Diffuse lamellar keratitis after corneal crosslinking in a patient with post-laser in situ keratomileusis corneal ectasia.
A 27-year-old man presented with corneal ectasia in his left eye 4 years after myopic laser in situ keratomileusis (LASIK) and was treated with riboflavin-ultraviolet-A (crosslinking). During the first post-treatment days, diffuse lamellar keratitis (DLK) (stage III) developed. The microbiology culture was negative. After intensive treatment with topical corticosteroids, the DLK resolved during the following 2 weeks. Crosslinking for post-LASIK corneal ectasia may induce DLK. Early diagnosis and appropriate treatment with intensive topical corticosteroids is essential to successfully manage this post-crosslinking complication.
Kymionis
George D
GD
Institute of Vision and Optics, University of Crete, Medical School, Department of Opthamology, Crete, Greece. kymionis@med.uoc.gr
Bouzoukis
Dimitrios I
DI
Diakonis
Vasilios F
VF
Portaliou
Dimitra M
DM
Pallikaris
Aristofanis I
AI
Yoo
Sonia H
SH
D000328:Adult; D003094:Collagen / Q000378:metabolism*; D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D004108:Dilatation, Pathologic / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007634:Keratitis / Q000188:drug therapy / Q000209:etiology*; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D008297:Male; D009216:Myopia / Q000601:surgery; D017319:Photosensitizing Agents / Q000009:adverse effects*; D012256:Riboflavin / Q000009:adverse effects; D014466:Ultraviolet Rays
D005938:Glucocorticoids; D017319:Photosensitizing Agents; D003907:Dexamethasone; D003094:Collagen; D012256:Riboflavin